skin. They received graded doses of guinea pig serum, equivalent to 40, 120 and 240 units, or E. coli asparaginase (300, 1000 and 2000 units), either alone or with 1 ml. of human serum added. Control animals received 1 ml. of Eagle's medium or 1 ml. of human serum only. These regimes were given either at the time of implantation of cells, or 7 days later when the tumour was well established, at which time the mean diameter was 7-8 mm. In experiments involving plasma fractions 1 dose of E. coli asparaginase (300 units) was used and the regime given only at the same time as the inoculation of the tumour cells.
To assess tumour growth, tumour diameter was measured in 3 directions and the mean taken. This observation was made daily following the occurrence of a palpable tumour. The intervals in days between inoculation of cells, occurrence of tumour and death were noted.
RESULTS
In those mice given 1 ml. of Eagle's medium, tumours were palpable after 6 days and death occurred after 15 days, at which time the mean diameter of the tumour was 22 mm. (Fig. 1 were given, the intervals before the occurrence of the tumour were 6, 10 and 16 days respectively and death occurred at 18, 23 and 33 days; the rate of tumour growth and the ultimate size were not altered. This is shown for one animal given 120 units in Fig. 2 . Identical doses of guinea pig serum asparaginase, given when the tumour was well established, caused temporary slight regression but the interval to death was not altered, being 18, 16 and 19 days respectively, as compared with those animals given only Eagle's medium, which died at 15 days (Fig. 3) . If 1 ml. of human serum was added to the various doses of guinea pig serum, given either with the tumour cells or later, no difference in tumour inhibition was observed (Table I ). Animals given 1 ml. of human serum showed the same pattern of results as those given only Eagle's medium. E. coli asparaginase was used in doses of 300, 1000 and 2000 units. When these were given at the time of the inoculation of cells it was only with the largest dose that the interval to the occurrence of a palpable tumour was altered, being 9 days, whereas with the controls and those given lower doses it was 6 days (Table II) . Once the tumour became established the rate of growth in all groups was similar and at death the tumours were the same size. Alteration ofthe interval until death was seen only with the largest dose, being 23 days, compared with 18 days in the controls and 19 and 21 days in the animals given lower doses of asparaginase. treated animals was similar to that seen in the controls (Fig. 4, 5) . A similar pattern of results was seen when human serum was given with 1000 and 2000 units of asparaginase (Table II) . When E. coli asparaginase was given at the time when the tumour was well established, significant benefit was obtained at all dose levels. Thus in those given Eagle's medium death occurred in 18 days, whereas those given 300, 1000 and Table II ). In an attempt to define which serum fraction, if any, was responsible for the effect seen when E. coli asparaginase plus human serum was given concurrently with the tumour cell inoculation, experiments were set up in which the following plasma fractions were substituted for whole serum-fibrinogen, gamma beta and alpha globulins and albumin. These were made up to give a total protein of 7 g. %, which was the same as when whole human serum was used. All animals given asparaginase received 300 units and it was found that all fractions tested had a similar effect to human serum, in that both the interval to the occurrence of tumour and death were prolonged (Table III) . The response to l-asparaginase of the mouse leukaemia system used in these experiments has been reported by and our results are very similar. They also found asparaginase, as contained in extracts from E. coli, to be much less effective if given at the time of inoculation than if given some days later when tumour growth was well established. Asparaginase, as contained in guinea pig serum, however, is more effective if given with the cells, although it will inhibit the growth of an established tumour . The difference in the pattern of action of the two asparaginases has been seen with various other mouse leukaemia systems, including the Gardner lymphosarcoma in C3H mice (Broome, 1963) . 1-Asparaginase, as obtained from different sources, varies widely in its biological behaviour. Thus the enzymes obtained from chicken liver, yeast, B. coagulans are ineffective, whereas those from guinea pig serum, E. coli, Serratia marcescens and Erwinia carotovora are effective tumour inhibitors (Ohnuma et al., 1967; Broome, 1965; Manning and Campbell, 1957; Mashburn and Wriston, 1964; Rowley and Wriston, 1967; Wade et al., 1968) . Broome (1965 Broome ( , 1968b has studied some of the factors which might influence tumour-inhibiting capacity of asparaginase from guinea pig serum and from E. coli, and found that the latter is more rapidly cleared from the circulation.
Thus 170 units of guinea pig serum had a half life in the mouse of 11 hours, while 150 units of E. coli asparaginase had a half life of 3 hours, and the biologically ineffective yeast enzyme was cleared in less than half an hour. The half life is not, however, the only factor determining the difference in activity, as the avidity of the enzymes for substrate at physiological levels also varies (Schwartz, Reeves and Broome, 1966; Broome, 1968c) . The importance of clearance rates has been emphasised by the demonstration that, in mice previously infected with L.D.H. virus, E. coli asparaginase is less rapidly cleared and its tumour inhibiting activity is increased Broome, 1968c ). Although we have not done clearance rate studies we would speculate that protein, as contained in human serum and its fractions, would cause stabilisation of the asparaginase molecule and thus lengthen its half life. The fact that the various plasma fractions were as equally effective as whole serum would support the view that the action of serum is a non-specific one, due to its protein content rather than any specific interaction between the enzyme and the serum component.
The therapeutic value of asparaginase is not yet established, but it has great attraction because it is the " first example of a chemotherapeutic agent based on a biochemical difference between the normal and malignant cells " (Lancet, 1968) . This biochemical difference can be measured in vitro, and thus one can predict the response of any particular leukaemic patient (Sobin and Kidd, 1966; Oettgen et al., 1968) . As asparaginase is likely to be in short supply for some time, it is important to define its optimum method of use. The present work would indicate that it might be of interest to study the protein content of solutions in which the enzyme is prepared.
SUMMARY
The effect of the addition of human serum on the anti-tumour activity of l-asparaginase, as contained in extracts of E. coli and guinea pig serum, was assessed using the mouse leukaemia system (EARAD/1). It was found that ifhuman serum and E. coli asparaginase were given simultaneously with the inoculation of the tumour cells, then the tumour inhibiting property of the enzyme was increased, whereas this effect was not seen if the asparaginase and serum were given when tumour growth was established. The addition of human to guinea pig serum did not influence its activity whether given when the tumour cells were inoculated, or when the tumour was established.
